Roswitha Kammler

机构：Molecular Partners (Switzerland), International Breast Cancer Study Group · ORCID：0000-0002-5572-7894

发表论文 175 篇 · 总被引 3487 次 · h-index 26

代表论文

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial (2025 · Lung Cancer · 被引 8)
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17) (2025 · Annals of Oncology · 被引 4)
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial (2025 · The Breast · 被引 4)
Abstract RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17) (2025 · Clinical Cancer Research · 被引 3)
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials (2025 · JCO Precision Oncology · 被引 3)
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index (2025 · JAMA Network Open · 被引 2)